Add BrightSurf on Google Email

Should lowest-risk prostate ‘cancer’ still be called cancer? Study suggests changing the name could save lives

Researchers estimate that relabeling Grade Group 1 prostate cancer as a precancerous condition could reduce unnecessary treatment and prevent nearly 2,400 prostate cancer deaths annually. This change may encourage more men to get screened, potentially leading to fewer deaths from aggressive prostate cancer.

First-of-its-kind cell therapy clinical trial led by Children’s National shows promising long-term survival in children with aggressive brain tumors

A Phase I trial evaluated a novel multi-targeted T-cell therapy for children with deadly brain tumors, offering early evidence that the patient's own immune cells can reach and fight tumors while producing fewer severe side effects. The study suggests a safer and more effective approach for pediatric brain cancers.

SourceChildren's National Hospital·JournalNature Medicine·DateJun 30, 2026

Researchers find caregivers of children hospitalized for cancer, blood disorders at risk for food insecurity

A study by Wake Forest University School of Medicine found nearly one in five caregivers reported experiencing food insecurity during their child's hospital stay. Children whose caregivers faced food insecurity stayed in the hospital about a third longer on average, with higher rates of readmission within 30 days.

SourceWake Forest University School of Medicine·JournalPediatric Blood & Cancer·TypeSurvey·DateJun 18, 2026

Well-timed nudges help care providers to honor the wishes of patients with cancer according to JNCCN study

Researchers developed a two-pronged approach to encourage important conversations between patients with cancer and their oncologists about goals and preferences for care. The study found that combining reminders for both patients and providers at the right moment significantly increased serious illness conversations.

SourceNational Comprehensive Cancer Network·JournalJournal of the National Comprehensive Cancer Network·TypeRandomized controlled/clinical trial·DateJun 15, 2026

UCLA researchers awarded NIH grant to improve detection and treatment of glioblastoma

Researchers at UCLA Jonsson Comprehensive Cancer Center have been awarded a $3.2 million NIH grant to develop advanced imaging and surgical strategies for improving glioblastoma outcomes. The team aims to use pH-based imaging to guide precise tumor removal and explore targeted therapies that target the tumor's acid-regulating systems.

Active β-catenin identified as a driver of aggressive pediatric osteosarcoma

A new study published in Genes & Cancer identifies activated beta-catenin as a key driver of aggressive pediatric osteosarcoma progression. The researchers found that cells expressing active beta-catenin exhibited enhanced invasive capacity and cancer-associated traits, suggesting a potential therapeutic target for this aggressive cancer.

SourceImpact Journals LLC·JournalGenes & Cancer·TypeNews article·DateJun 9, 2026

Experimental compounds trigger cancer cell death in KRAS-driven pancreatic cancer

Researchers investigated polyisoprenylated cysteinyl amide inhibitors (PCAIs) for their anticancer effects on pancreatic cancer cells with KRAS mutations. The compounds demonstrated strong activity against cell survival, migration, and invasion pathways. PCAI treatment caused hyperactivation of MAPK and PI3K/AKT pathways, leading to ox...

SourceImpact Journals LLC·JournalOncotarget·TypeNews article·DateJun 8, 2026

Alliance digital tool proves effective at keeping patients engaged in trials

A pilot study of the Participant Engagement Portal (PEP) tool shows that 84% of participants had a positive experience, with high usability and satisfaction rates. PEP facilitates two-way communication between patients and clinicians, allowing for self-reporting of social risk factors and future research opportunities.

SourceAlliance for Clinical Trials in Oncology·JournalJNCI Cancer Spectrum·TypeSurvey·DateJun 8, 2026

Weight loss treatments linked to lower risk of obesity-related cancers in people without diabetes

A study of over 229,000 obese adults without diabetes found that weight loss drugs, such as semaglutide and tirzepatide, were associated with a 41% decrease in the overall risk of developing obesity-related cancers. GLP-1 RAs also showed larger reductions in certain subgroups, including men and gynaecologic cancers.

SourceEuropean Society for Medical Oncology·JournalAnnals of Oncology·TypeObservational study·DateJun 7, 2026

Can taking aspirin uncover asymptomatic bladder cancer?

Researchers analyzed data from over 50,000 adults who started taking aspirin and found a similar bladder cancer prevalence but lower invasive stage. Aspirin initiators received more cystoscopies, which uncovered the cancer. The study suggests that aspirin may unmask otherwise asymptomatic bladder cancer.

SourceWiley·JournalJournal of Internal Medicine·DateJun 3, 2026

Cancer diagnostic delay rates associated with a population-based screening trial evaluating a cell-free DNA multicancer early detection test

A population-based screening trial evaluating a cell-free DNA multicancer early detection test found modest increases in diagnostic delay rates for head and neck, lung, and upper gastrointestinal cancers. These findings suggest that future trials may need to consider system-level spillover effects on healthcare resources.

SourceJAMA Network·JournalJAMA·DateMay 30, 2026

ASCO: Tile-based radiation therapy lowers risk of recurrence in brain metastases

A multicenter clinical trial found that implanting collagen tiles during brain surgery improved tumor control and lowered the risk of recurrence by 12.1% compared to current standard of care. Patients treated with tile-based radiation therapy (TBRT) had a median overall survival of 42.5 months, more than double the 17.6 months seen wit...

SourceUniversity of Texas M. D. Anderson Cancer Center·TypeRandomized controlled/clinical trial·DateMay 30, 2026